Copyright
©The Author(s) 2021.
World J Gastrointest Oncol. Nov 15, 2021; 13(11): 1813-1832
Published online Nov 15, 2021. doi: 10.4251/wjgo.v13.i11.1813
Published online Nov 15, 2021. doi: 10.4251/wjgo.v13.i11.1813
Finn et al[12], 2020 | Lee et al[16], 2020 | ||||
Interventional arm | Control arm | Interventional arm | Control arm | ||
Atezolizumab-bevacizumab combination therapy | Sorafenib monotherapy | Atezolizumab-bevacizumab combination therapy given in both Arms A and F | Atezolizumab monotherapy | ||
Group A | Group F+ | ||||
n = 336 | n = 165 | n = 104 | n = 60 | n = 59 | |
Median age (IQR), yr | 64 (56-71) | 66 (59-71) | 62 (23-82) | 60 (22-82) | 63 (23-85) |
Gender, n (%) | |||||
Male | 277 (82) | 137 (83) | 84 (81) | 54 (90) | 49 (83) |
Female | 59 (18) | 28 (17) | 20 (19) | 6 (10) | 10 (17) |
Race, n (%) | |||||
White | 123 (37) | 52 (32) | 20 (19) | 14 (23) | 9 (15) |
Asian | 188 (56) | 96 (58) | 75 (72) | 45 (75) | 47 (80) |
Black or African American | 6 (1.8) | 4 (2.4) | 7 (7) | 1 (2) | 2 (3) |
Native Hawaiian or other Pacific Islander | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (2) |
Unknown | 19 (6) | 12 (7) | 2 (2) | 0 (0) | 0 (0) |
Geographic region, n (%) | |||||
Asian excluding Japan | 133 (40) | 68 (41) | 59 (57) | 39 (65) | 39 (66) |
Rest of the world (United States, Australia, New Zealand, and Japan) | 203 (60) | 97 (59) | 45 (43) | 21 (35) | 20 (34) |
Child Pugh, n (%) | |||||
Child Pugh A5 | 239 (72) | 121 (73) | 77 (74) | 43 (72) | 42 (71) |
Child Pugh A6 | 94 (28) | 44 (27) | 21 (20) | 17 (28) | 17 (29) |
Child Pugh A7 | 0 (0) | 0 | 6 (6) | 17 (28) | 17 (29) |
Child Pugh B | 1 (< 1) | 0 (0) | NA | NA | NA |
ECOG performance status, n (%) | |||||
ECOG 0 | 209 (62) | 103 (62) | 52 (50) | 27 (45) | 25 (42) |
ECOG 1 | 127 (38) | 62 (38) | 52 (50) | 33 (55) | 34 (58) |
BCLC, n (%) | |||||
BCLC stage A (early) | 8 (2) | 6 (4) | 0 (0) | 0 (0) | 2 (3) |
BCLC stage B (intermediate) | 52 (15) | 26 (16) | 10 (10) | 6 (10) | 4 (7) |
BCLC stage C (advanced) | 276 (82) | 133 (81) | 94 (90) | 54 (90) | 53 (90) |
Alpha-fetoprotein > 400 ng per milliliter | 126 (38%) | 61 (37%) | 37 (36%) | 18 (30%) | 19 (32%) |
Macrovascular invasion | 129 (38%) | 71 (43%) | 55 (53%) | 20 (33%) | 25 (42%) |
Extrahepatic spread | 212 (63%) | 93 (56%) | 91 (88%) | 47 (78%) | 50 (85%) |
Hepatitis B | 164 (49%) | 76 (46%) | 51 (49%) | 34 (57%) | 32 (54%) |
Hepatitis C | 72 (21%) | 36 (22%) | 31 (30%) | 11 (18%) | 10 (17%) |
Non-viral | 100 (30%) | 85 (52%) | 22 (21%) | 15 (25%) | 17 (29%) |
Alcohol use, n (%) | |||||
Previous | 166 (50) | 79 (48) | 58 (56) | 39 (65) | 32 (54) |
Never | 121 (36) | 61 (37) | 32 (31) | 14 (23) | 21 (36) |
Current | 48 (14) | 25 (15) | 14 (13) | 7 (12) | 6 (10) |
Varices at baseline | 88 (26%) | 43 (26%) | NA | NA | NA |
Varices treated at baseline | 36 (11%) | 23 (14%) | NA | NA | NA |
PD-L1 status, n (%) | 124 | 58 | NA | NA | NA |
TC and IC < 1% | 45 (36) | 25 (43) | 25 (24) | 15 (25) | 18 (31) |
TC or IC ≥ 1% | 79 (64) | 33 (57) | 61 (59) | 28 (47) | 34 (58) |
TC ≥ 5% or IC ≥ 5% | 46 (37) | 17 (29) | 37 (36) | 8 (13) | 16 (27) |
TC ≥ 10% or IC ≥ 10% | 12 (10) | 5 (9) | 30 (29) | 5 (8) | 6 (10) |
Data missing | NA | NA | 18 (17) | 17 (28) | 8 (14) |
Prior local therapy for HCC, n (%) | |||||
At least one treatment | 161 (48) | 85 (52) | NA | NA | NA |
Transarterial chemoembolization | 130 (39) | 70 (42) | NA | NA | NA |
Radiofrequency ablation | 47 (14) | 24 (15) | NA | NA | NA |
Prior radiotherapy | 34 (10) | 17 (10) | NA | NA | NA |
- Citation: Ahmed F, Onwumeh-Okwundu J, Yukselen Z, Endaya Coronel MK, Zaidi M, Guntipalli P, Garimella V, Gudapati S, Mezidor MD, Andrews K, Mouchli M, Shahini E. Atezolizumab plus bevacizumab versus sorafenib or atezolizumab alone for unresectable hepatocellular carcinoma: A systematic review. World J Gastrointest Oncol 2021; 13(11): 1813-1832
- URL: https://www.wjgnet.com/1948-5204/full/v13/i11/1813.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v13.i11.1813